# Pharmacogenomics of surgical stress response in elective abdominal surgeries

## TL;DR

This study explores how genetic differences affect surgical stress and recovery, showing that personalized drug management can improve outcomes.

## Contribution

The study identifies pharmacogenetic variants linked to surgical stress response and demonstrates the benefits of pharmacogenomic-guided care.

## Key findings

- Patients with certain genetic variants had lower IL-6 levels and fewer complications.
- Pharmacogenomic-guided therapy reduced opioid requirements and improved recovery.
- Genetic testing could help tailor perioperative management for better surgical outcomes.

## Abstract

The variability in surgical stress response among patients undergoing elective abdominal surgeries remains inadequately understood,
particularly in relation to genetic polymorphisms influencing drug metabolism and pain modulation. Hence, this study explored the
association between key pharmacogenetic variants (CYP2D6, CYP3A4, OPRM1 and COMT) and biomarkers of surgical stress response. A total of
240 patients were evaluated, with half receiving pharmacogenomic-guided perioperative management. Significant differences were observed
in IL-6 levels, opioid requirements and complication rates between genotypic groups. Pharmacogenomic-guided therapy effectively reduced
postoperative complications and improved recovery, underscoring its potential for personalized surgical care.